No change on serum neurofilament light chain concentrations in patients with multiple sclerosis switching from 4 to 6 weeks interval between natalizumab infusions

被引：0
|
作者：
Johnsson, M. [1 ]
Farman, H. [1 ]
Lycke, J. [1 ]
Novakova, L. [1 ]
Malmestrom, C. [1 ]
Zetterberg, H. [2 ,3 ,4 ,5 ]
Blennow, K. [2 ,3 ]
Axelsson, M. [1 ]
机构：
[1] Sahlgrens Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden
[2] Sahlgrens Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
[4] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England
[5] UCL, UK Dementia Res Inst, London, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P936
引用
收藏
页码：764 / 764
页数：1
相关论文
共 50 条
  • [31] Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis
    Comabella, Manuel
    Sastre-Garriga, Jaume
    Carbonell-Mirabent, Pere
    Fissolo, Nicolas
    Tur, Carmen
    Malhotra, Sunny
    Pareto, Deborah
    Aymerich, Francesc X.
    Rio, Jordi
    Rovira, Alex
    Tintore, Mar
    Montalban, Xavier
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (07): : 732 - 740
  • [32] Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients
    Jakimovski, Dejan
    Gibney, Brianna L.
    Marr, Karen
    Ramasamy, Deepa P.
    Dwyer, Michael G.
    Bergsland, Niels
    Weinstock-Guttman, Bianca
    Ramanathan, Murali
    Zivadinov, Robert
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (08) : 2299 - 2308
  • [33] Serum Neurofilament Light Chain Levels as a Biomarker of Disease Activity and Treatment Response in Patients with Progressive and Relapsing Multiple Sclerosis
    Pedrini, Marzena
    Kaskow, Belinda
    Trend, Stephanie
    Carroll, William
    Walters, Susan
    Maceski, Aleksandra
    Kuhle, Jens
    Kermode, Allan
    NEUROLOGY, 2023, 100 (17)
  • [34] Serum neurofilament light chain levels during natalizumab treatment with every-4-week and every-6-week dosing in NOVA
    Giovannoni, G.
    Foley, J.
    Defer, G.
    Ryerson, L. Zhovtis
    Cohen, J.
    Arnold, D.
    Butzkueven, H.
    Cutter, G.
    Killestein, J.
    Wiendl, H.
    Sinks, S.
    Steverson, J.
    Dsilva, L.
    Monine, M.
    Sohn, J.
    Ferraro, E.
    Lasky, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 528 - 529
  • [35] Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment
    Chow, Helene Hojsgaard
    Petersen, Eva Rosa
    Olsson, Anna
    Laursen, Julie Hejgaard
    Hansen, Malene Bredahl
    Oturai, Annette Bang
    Sorensen, Per Soelberg
    Sondergaard, Helle Bach
    Sellebjerg, Finn
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 88
  • [36] Serum neurofilament light chain in a cohort of multiple sclerosis, MOG-antibody diseases and neuromyelitis optica spectrum disorders patients
    Bollo, Luca
    Iaffaldano, Pietro
    Ruggieri, Maddalena
    Palazzo, Claudia
    Guerra, Tommaso
    Caputo, Francesca
    Mastrapasqua, Mariangela
    Manni, Alessia
    Paolicelli, Damiano
    Simone, Marta
    Frigeri, Antonio
    Trojano, Maria
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [37] Serum neurofilament light chain and glial fibrillary acid protein analysis in patients with multiple sclerosis: a clue to distinguish inflammation and neurodegeneration?
    Ayrignac, X.
    Maleska-Maceski, A.
    Carra-Dalliere, C.
    Charif, M.
    Catteau, C.
    Ginestet, N.
    Prin, P.
    Corti, L.
    Pinna, F.
    Lehmann, S.
    Labauge, P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 1002 - 1003
  • [38] Alemtuzumab reduces serum neurofilament light chain levels in relapsing-remitting multiple sclerosis patients from the CARE-MS I study
    Kuhle, J.
    Daizadeh, N.
    Barro, C.
    Michalak, Z.
    Godin, J.
    Shankara, S.
    Samad, T. A.
    Jacobs, A.
    Chung, L.
    Roesch, N.
    Kaiser, C.
    Havari, E.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 994 - 995
  • [39] Serum Neurofilament Light Chain Levels Correlate with Disease Characteristics in Patients with Relapsing-Remitting Multiple Sclerosis from CARE-MS I
    Kuhle, Jens
    Daizadeh, Nadia
    Barro, Christian
    Michalak, Zuzanna
    Leppert, David
    Godin, Jean
    Shankara, Srinivas
    Samad, Tarek
    Jacobs, Alan
    Chung, Luke
    Roesch, Nora
    Kaiser, Carina
    Havari, Evis
    Kappos, Ludwig
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 30 - 30
  • [40] Blood Neurofilament Light Chain Levels and Association with Brain Volume Change in Patients with Primary Progressive Multiple Sclerosis and Relapsing Multiple Sclerosis Before and During Ocrelizumab Treatment
    Jia, Xiaoming
    Herman, Ann
    Harp, Christopher
    Cross, Anne
    Fiore, Damian
    Hauser, Stephen
    Kappos, Ludwig
    Koendgen, Harold
    Kuhle, Jens
    Leppert, David
    Manfrini, Marianna
    Model, Fabian
    Oksenberg, Jorge
    Sauter, Annette
    Thanei, Gian-Andrea
    Bar-Or, Amit
    NEUROLOGY, 2020, 94 (15)
12345